New Study Shows the Benefits of BioWave® Nerve Stimulation to Treat Chronic Pain

On February 20, 2023, the peer reviewed journal, Pain and Therapy, published a new study titled "Reduced Pain and Improved Function Following Short-Term Use of Noninvasive BioWave High Frequency Peripheral Nerve Stimulation for Pain Management" by Alaa Abd-Elsayed, Michael Gyorfi, Michael Fishman, Charles Odonkor, Bradford Siff, and Kevin Cyr.

The paper confirmed smaller prior studies about the benefits of BioWave® technology to treat chronic pain. The size of the patient population (1511 patients) is amongst the largest population sizes ever studied for noninvasive peripheral nerve stimulation. The study looked at the use of the BioWaveHOME® device in chronic pain treatment. Patients experienced significant reduction in overall pain and medication needs in just two weeks of starting to use BioWave®.

BioWave® is a patented smarter pain blocking technology that provides immediate, deep, long-lasting relief of severe pain. BioWave devices deliver therapeutic electrical signals through skin directly to pain nerves in deep tissue to prevent pain from reaching the brain relieving chronic, acute or post-operative pain. BioWave technology provides 8 hours of pain relief on average following a 30-minute treatment*. It is easy to use at home or on the go.

The five main outcomes the study found were: overall pain reduction after using BioWave for two weeks was 46%. The average reduction in pain score was 3.47 points (0-10 scale), which is a significant reduction. An improvement in quality of life was reported in 87.6% of patients; 42% of patients reported they were able to eliminate or reduce their medication. Over 97% of patients wanted to continue the BioWave therapy. Most importantly the effect on functional lifestyle (mood, sleep, standing, sitting, etc.) was improved across the board. There were no adverse reactions or complications reported in the 1511 patient outcomes.

"Although survey studies have inherent limitations such as duration and compliance biases with such an overwhelming benefit in every category, we believe that noninvasive neuromodulation therapy is a promising, safe, and cost-effective therapy," wrote the authors.

"The recent study confirms the efficacy of our patented high frequency pain blocking technology for the treatment of severe chronic pain, and for improvement in function and qualities of life for patients," said Brad Siff, Founder & President of BioWave Corporation. "Our mission is to help people win their battle with severe pain so they can get back to their daily activities. BioWave is changing lives every day and it's extremely rewarding to be able to help these patients who suffer from pain. The published clinical paper demonstrates our dedication to providing proven, innovative efficacy for our customers," said Brad Siff.